After Vanda Pharmaceuticals’ phase 3 miss and FDA rejection for its stomach disorder candidate, CEO Mihael Polymeropoulos, M.D., is calling…

It’s been a rough month for several clinical amyotrophic lateral sclerosis (ALS) candidates, but that’s not stopping Eli Lilly from…

Fiber has long been heralded as a cornerstone of a nutritious diet, contributing significantly to overall health and wellness. Despite…

A groundbreaking development in cancer diagnostics has emerged from the collaborative research conducted at the Francis Crick Institute and the…

The race to enhance quantum computing technology has taken a significant turn with the development of an innovative quantum refrigerator…

In the wake of the 2015 emissions scandal that shook the automotive industry, the conversation around realistic vehicle emissions testing…

Eliem Therapeutics is continuing its transformation into an immune-mediated disease company by paying $9 million to license a Chinese biotech’s…

The J.P. Morgan Healthcare Conference in San Francisco is back for 2025 and here at Fierce Biotech, we’re going to…

Bayer’s hot flash drug candidate has hit the mark in a phase 3 breast cancer trial, potentially positioning the German drugmaker…

On Astellas Pharma’s mission to develop new cell therapies in cancers and other diseases, not all candidates are destined to…